Aduro Biotech Inc., of Berkeley, Calif., reported Wednesday that all its clinical trials will continue unaltered and as planned, quelling fears of a possible FDA clinical hold that emerged after the company reported in an SEC filing that one patient receiving its listeria-based therapy, CRS-207, developed listeriosis, a potentially fatal infection for immuno-compromised patients caused by listeria.